Celgene ROE 2006-2019 | CELG

Current and historical return on equity (ROE) values for Celgene (CELG) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Celgene ROE for the three months ending March 31, 2019 was 106.69%.
Celgene ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2019-03-31 $4.75B $8.17B 83.92%
2018-12-31 $4.05B $6.16B 82.47%
2018-09-30 $2.89B $4.86B 56.75%
2018-06-30 $2.80B $3.43B 44.11%
2018-03-31 $2.85B $5.17B 37.57%
2017-12-31 $2.94B $6.92B 35.79%
2017-09-30 $3.45B $9.85B 42.41%
2017-06-30 $2.63B $8.45B 37.16%
2017-03-31 $2.13B $7.64B 33.49%
2016-12-31 $2.00B $6.60B 34.96%
2016-09-30 $2.13B $5.65B 38.41%
2016-06-30 $1.93B $5.55B 35.15%
2016-03-31 $1.68B $5.08B 29.68%
2015-12-31 $1.60B $5.92B 26.28%
2015-09-30 $1.66B $5.38B 26.49%
2015-06-30 $2.20B $6.32B 34.64%
2015-03-31 $2.44B $6.77B 40.82%
2014-12-31 $2.00B $6.53B 37.01%
2014-09-30 $1.60B $5.77B 30.95%
2014-06-30 $1.47B $4.85B 28.14%
2014-03-31 $1.35B $4.49B 25.17%
2013-12-31 $1.45B $5.59B 25.84%
2013-09-30 $1.50B $5.90B 26.59%
2013-06-30 $1.55B $5.41B 27.70%
2013-03-31 $1.44B $5.55B 25.10%
2012-12-31 $1.46B $5.70B 24.83%
2012-09-30 $1.60B $5.73B 27.55%
2012-06-30 $1.55B $5.96B 26.81%
2012-03-31 $1.46B $6.08B 25.25%
2011-12-31 $1.32B $5.51B 22.93%
2011-09-30 $1.12B $5.61B 19.05%
2011-06-30 $1.03B $6.00B 17.83%
2011-03-31 $0.90B $5.88B 16.44%
2010-12-31 $0.88B $6.00B 16.90%
2010-09-30 $0.92B $5.15B 19.22%
2010-06-30 $0.86B $4.93B 18.91%
2010-03-31 $0.85B $4.76B 19.80%
2009-12-31 $0.78B $4.40B 19.28%
2009-09-30 $0.37B $4.11B 9.83%
2009-06-30 $0.29B $3.86B 8.00%
2009-03-31 $0.27B $3.76B 7.60%
2008-12-31 $-1.53B $3.49B -45.30%
2008-09-30 $-1.31B $3.59B -40.63%
2008-06-30 $-1.41B $3.43B -47.78%
2008-03-31 $-1.47B $3.03B -55.34%
2007-12-31 $0.23B $2.84B 9.29%
2007-09-30 $0.17B $2.48B 7.85%
2007-06-30 $0.16B $2.29B 8.59%
2007-03-31 $0.11B $2.12B 7.75%
2006-12-31 $0.07B $1.98B 6.45%
2006-09-30 $0.05B $0.84B 6.81%
2006-06-30 $0.03B $0.75B 4.62%
2006-03-31 $0.03B $0.72B 5.12%
2005-12-31 $0.06B $0.64B 11.06%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $64.715B $15.281B
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Their portfolio of commercial products include REVLIMID, VIDAZA, THALOMID, POMALYST/IMNOVID, ABRAXANE, OTEZLA, ISTODAX and IDHIFA. The drug candidates in their pipeline are at various stages of preclinical and clinical development. These candidates include their IMiDs compounds, which are a proprietary class of compounds that have certain immunomodulatory and other biologically important properties in addition to their leading oral anti-inflammatory agents and cellular therapies. They believe their commercial stage products and the depth of their product pipeline, provide the catalysts for future growth.
Stock Name Country Market Cap PE Ratio
Amgen (AMGN) United States $107.422B 12.15
Gilead Sciences (GILD) United States $86.782B 10.54
Biogen (BIIB) United States $45.297B 8.60
Vertex Pharmaceuticals (VRTX) United States $45.172B 54.60
Illumina (ILMN) United States $44.437B 51.50
CSL (CSLLY) Australia $35.310B 0.00
Regeneron Pharmaceuticals (REGN) United States $32.586B 15.32
Actelion (ALIOF) Switzerland $29.891B 0.00
Alexion Pharmaceuticals (ALXN) United States $27.590B 15.61
Incyte (INCY) United States $17.453B 70.77
BioMarin Pharmaceutical (BMRN) United States $15.040B 0.00
Exact Sciences (EXAS) United States $15.005B 0.00
SINO PHARMACEUT (SBMFF) China $14.407B 0.00
Sarepta Therapeutics (SRPT) United States $11.635B 0.00
Genmab (GNMSF) Denmark $11.067B 56.26
Array BioPharma (ARRY) United States $10.358B 0.00
Seattle Genetics (SGEN) United States $10.323B 0.00
Bio-Rad Laboratories (BIO.B) United States $9.283B 49.21
QIAGEN (QGEN) Netherlands $9.032B 29.67
Galapagos (GLPG) Belgium $8.749B 0.00
Guardant Health (GH) United States $8.099B 0.00
Bio-Techne Corp (TECH) United States $7.974B 54.41
Alnylam Pharmaceuticals (ALNY) United States $7.755B 0.00
Bluebird Bio (BLUE) United States $7.483B 0.00
Amarin (AMRN) Ireland $7.232B 0.00
Exelixis (EXEL) United States $6.464B 16.48
BeiGene (BGNE) Cayman Islands $5.733B 0.00
Ascendis Pharma (ASND) Denmark $4.717B 0.00
Moderna (MRNA) United States $4.711B 0.00
Blueprint Medicines (BPMC) United States $4.686B 0.00
ARGENX SE-ADR (ARGX) Netherlands $4.616B 0.00
Horizon Pharma Public (HZNP) Ireland $4.348B 11.20
Repligen (RGEN) United States $4.059B 101.12
ACADIA Pharmaceuticals (ACAD) United States $3.852B 0.00
Mirati Therapeutics (MRTX) United States $3.805B 0.00
Spark Therapeutics (ONCE) United States $3.765B 0.00
China Biologic Products (CBPO) China $3.689B 23.43
Alkermes (ALKS) Ireland $3.662B 0.00
Ultragenyx Pharmaceutical (RARE) United States $3.369B 0.00
MorphoSys AG (MOR) Germany $3.287B 0.00
Arena Pharmaceuticals (ARNA) United States $3.077B 6.25
Amicus Therapeutics (FOLD) United States $2.888B 0.00
Immunomedics (IMMU) United States $2.724B 0.00
Medicines (MDCO) United States $2.713B 0.00
UniQure (QURE) Netherlands $2.633B 0.00
CRISPR Therapeutics AG (CRSP) Switzerland $2.607B 0.00
Reata Pharmaceuticals (RETA) United States $2.582B 0.00
Halozyme Therapeutics (HALO) United States $2.461B 0.00
Nabriva Therapeutics AG (NBRV) Ireland $2.328B 0.00
MyoKardia (MYOK) United States $2.314B 0.00
Ligand Pharmaceuticals (LGND) United States $2.291B 18.98
Emergent Biosolutions (EBS) United States $2.238B 19.44
Akcea Therapeutics (AKCA) United States $2.178B 0.00
Acceleron Pharma (XLRN) United States $2.159B 0.00
NeoGenomics (NEO) United States $2.133B 139.63
Genomic Health (GHDX) United States $2.121B 45.04
Zai Lab (ZLAB) China $2.116B 0.00
Intercept Pharmaceuticals (ICPT) United States $2.064B 0.00
Denali Therapeutics (DNLI) United States $1.970B 0.00
Myriad Genetics (MYGN) United States $1.912B 19.02
REGENXBIO (RGNX) United States $1.759B 0.00
Insmed (INSM) United States $1.725B 0.00
Cambrex (CBM) United States $1.523B 19.25
AnaptysBio (ANAB) United States $1.504B 0.00
Fate Therapeutics (FATE) United States $1.443B 0.00
Innoviva (INVA) United States $1.428B 3.95
RA PHARMCTL INC (RARX) United States $1.404B 0.00
Sangamo Therapeutics (SGMO) United States $1.384B 0.00
Athenex (ATNX) United States $1.341B 0.00
Alector (ALEC) United States $1.309B 0.00
Coherus BioSciences (CHRS) United States $1.308B 0.00
Editas Medicine (EDIT) United States $1.245B 0.00
Epizyme (EPZM) United States $1.240B 0.00
Orchard Therapeutics (ORTX) United Kingdom $1.188B 0.00
Momenta Pharmaceuticals (MNTA) United States $1.050B 0.00
Codexis (CDXS) United States $1.022B 0.00
Cara Therapeutics (CARA) United States $1.010B 0.00
Adverum Biotechnologies (ADVM) United States $0.986B 0.00
ANI Pharmaceuticals (ANIP) United States $0.973B 17.26
Dicerna Pharmaceuticals (DRNA) United States $0.970B 0.00
Alder BioPharmaceuticals (ALDR) United States $0.950B 0.00
Principia Biopharma (PRNB) United States $0.945B 0.00
Twist Bioscience (TWST) United States $0.942B 0.00
Zymeworks (ZYME) Canada $0.936B 0.00
WAVE Life Sciences (WVE) Singapore $0.925B 0.00
ZIOPHARM Oncology Inc (ZIOP) United States $0.924B 0.00
Retrophin (RTRX) United States $0.879B 0.00
Vericel (VCEL) United States $0.861B 0.00
BAVARIAN NORDIC (BVNRY) Denmark $0.856B 0.00
Arvinas (ARVN) United States $0.805B 0.00
Intellia Therapeutics (NTLA) United States $0.767B 0.00
Vanda Pharmaceuticals (VNDA) United States $0.719B 33.92
Precision BioSciences (DTIL) United States $0.693B 0.00
Clovis Oncology (CLVS) United States $0.687B 0.00
Zealand Pharma (ZLDPF) Denmark $0.683B 0.00
Zealand Pharma (ZEAL) Denmark $0.676B 7.90
Cellectis S.A (CLLS) France $0.654B 0.00
Autolus Therapeutics (AUTL) United Kingdom $0.646B 0.00
Cytokineticsorporated (CYTK) United States $0.639B 0.00
Lexicon Pharmaceuticals (LXRX) United States $0.631B 0.00
Intra-Cellular Therapies (ITCI) United States $0.630B 0.00
Heska (HSKA) United States $0.629B 64.40
DBV Technologies S.A (DBVT) France $0.621B 0.00
OXFORD BIOMEDCL (OXBDF) United Kingdom $0.575B 0.00
Anika Therapeutics (ANIK) United States $0.573B 19.58
MiMedx (MDXG) United States $0.561B 0.00
Revance Therapeutics (RVNC) United States $0.552B 0.00
Stemline Therapeutics (STML) United States $0.551B 0.00
CytomX Therapeutics (CTMX) United States $0.534B 0.00
Pharming Group (PHGUF) Netherlands $0.521B 0.00
Mesoblast (MESO) Australia $0.503B 0.00
PHARMA MAR SA (PHMMF) Spain $0.459B 0.00
UROGEN PHARMA (URGN) United States $0.446B 0.00
Basilea Pharmaceutica AG (BPMUF) Switzerland $0.442B 0.00
Puma Biotechnology (PBYI) United States $0.433B 0.00
Gritstone Oncology (GRTS) United States $0.395B 0.00
Prothena (PRTA) Ireland $0.386B 0.00
Biofrontera AG (BFRA) Germany $0.385B 0.00
Scholar Rock Holding (SRRK) United States $0.376B 0.00
PDL BioPharma (PDLI) United States $0.373B 8.91
AC Immune SA (ACIU) Switzerland $0.372B 23.96
Arcus Biosciences (RCUS) United States $0.371B 0.00
Sinovac Biotech (SVA) China $0.371B 0.00
Adaptimmune Therapeutics (ADAP) United Kingdom $0.366B 0.00
Bellus Health (BLUSF) Canada $0.359B 0.00
Merus (MRUS) Netherlands $0.358B 0.00
Avid Bioservices (CDMO) United States $0.352B 0.00
BioDelivery Sciences (BDSI) United States $0.350B 0.00
Albireo Pharma (ALBO) United States $0.347B 0.00
Achillion Pharmaceuticals (ACHN) United States $0.343B 0.00
Prometic Life Sciences (PFSCD) Canada $0.341B 0.00
Agenus (AGEN) United States $0.341B 0.00
Senesco Technologies (ELOX) United States $0.338B 0.00
Starpharma Holdings (SPHRY) Australia $0.337B 0.00
Theratechnologies (THERF) Canada $0.330B 0.00
Kadmon Holdings (KDMN) United States $0.321B 0.00
Syros Pharmaceuticals (SYRS) United States $0.319B 0.00
Acorda Therapeutics (ACOR) United States $0.316B 5.56
AMAG Pharmaceuticals (AMAG) United States $0.312B 0.00
Sorrento Therapeutics (SRNE) United States $0.308B 0.00
Protagonist Therapeutics (PTGX) United States $0.308B 0.00
Kindred Biosciences (KIN) United States $0.305B 0.00
Inovio Pharmaceuticals (INO) United States $0.290B 0.00
Xenon Pharmaceuticals (XENE) Canada $0.271B 0.00
Cellular Biomedicine (CBMG) United States $0.266B 0.00
PHASEBIO PHARMA (PHAS) United States $0.263B 0.00
Dynavax Technologies (DVAX) United States $0.263B 0.00
Sutro Biopharma (STRO) United States $0.262B 0.00
ChromaDex (CDXC) United States $0.250B 0.00
Syndax Pharmaceuticals (SNDX) United States $0.243B 0.00
Kamada (KMDA) Israel $0.236B 9.16
Athersys (ATHX) United States $0.234B 0.00
ADMA Biologics Inc (ADMA) United States $0.233B 0.00
Cel-Sci (CVM) United States $0.231B 0.00
Geron (GERN) United States $0.229B 0.00
Palatin Technologies (PTN) United States $0.226B 0.00
Pieris Pharmaceuticals (PIRS) United States $0.210B 0.00
Synlogic (SYBX) United States $0.210B 0.00
Cerecor (CERC) United States $0.208B 0.00
Abeona Therapeutics (ABEO) United States $0.207B 0.00
MannKind (MNKD) United States $0.205B 0.00
CorMedix Inc (CRMD) United States $0.204B 0.00
Five Prime Therapeutics (FPRX) United States $0.202B 0.00
Pfenex (PFNX) United States $0.197B 0.00
Affimed (AFMD) Germany $0.197B 0.00
Aeglea BioTherapeutics (AGLE) United States $0.196B 0.00
POXEL SA FRANCE (PXXLF) $0.194B 0.00
Mersana Therapeutics (MRSN) United States $0.190B 0.00
Spero Therapeutics (SPRO) United States $0.188B 0.00
OSMOTICA PHARM (OSMT) United States $0.187B 0.00
Enzo Biochem (ENZ) United States $0.185B 0.00
Arsanis (XFOR) United States $0.184B 0.00
BioTime (BTX) United States $0.180B 12.00
Compugen (CGEN) Israel $0.177B 0.00
Newron Pharmaceuticals SpA (NWPHF) $0.165B 0.00
Nicox SA (NICXF) France $0.163B 0.00
EYEPOINT PHARMACEUTICALS, INC (EYPT) United States $0.160B 0.00
XOMA (XOMA) United States $0.159B 0.00
Strongbridge Biopharma (SBBP) United States $0.155B 8.94
Liquidia Technologies (LQDA) United States $0.146B 0.00
Cue Biopharma (CUE) United States $0.144B 0.00
OvaScience (MLND) United States $0.144B 0.00
Celyad SA (CYAD) Belgium $0.140B 0.00
Adocia (ADOCY) France $0.140B 0.00
TOCAGEN INC (TOCA) United States $0.138B 0.00
Dyadic (DYAI) United States $0.138B 0.00
Northwest Biotherapeutics (NWBO) United States $0.133B 0.00
Arbutus Biopharma (ABUS) Canada $0.133B 0.00
Aptinyx (APTX) United States $0.128B 0.00
Aduro Biotech (ADRO) United States $0.122B 0.00
Menlo Therapeutics (MNLO) United States $0.119B 0.00
Paratek Pharmaceuticals (PRTK) United States $0.119B 0.00
AVEO Pharmaceuticals (AVEO) United States $0.117B 0.00
Alcobra (ARCT) United States $0.117B 0.00
Seres Therapeutics (MCRB) United States $0.115B 0.00
Novavax (NVAX) United States $0.111B 0.00
NantKwest (NK) United States $0.111B 0.00
Nymox Pharmaceutical (NYMX) Canada $0.110B 0.00
Verastem (VSTM) United States $0.108B 0.00
ASLAN Pharmaceuticals (ASLN) Singapore $0.103B 0.00
Catalyst Biosciences (CBIO) United States $0.100B 0.00
Fortress Biotech (FBIO) United States $0.099B 0.00
Trevena (TRVN) United States $0.098B 0.00
Checkpoint Therapeutics (CKPT) United States $0.098B 0.00
SESEN BIO, INC (SESN) United States $0.095B 0.00
Catabasis Pharmaceuticals (CATB) United States $0.086B 0.00
AquaBounty Technologies (AQB) United States $0.085B 0.00
ANIXA BIOSCIENCES INC (ANIX) United States $0.084B 0.00
Aridis Pharmaceuticals (ARDS) United States $0.084B 0.00
Curis (CRIS) United States $0.082B 0.00
VBI Vaccines (VBIV) United States $0.080B 0.00
Pluristem Therapeutics (PSTI) Israel $0.078B 0.00
Spring Bank Pharmaceuticals (SBPH) United States $0.078B 0.00
Selecta Biosciences (SELB) United States $0.077B 0.00
Merrimack Pharmaceuticals (MACK) United States $0.075B 0.00
Idera Pharmaceuticals (IDRA) United States $0.070B 0.00
Applied Genetic Technologies (AGTC) United States $0.069B 38.00
VTv Therapeutics (VTVT) United States $0.069B 0.00
Unum Therapeutics (UMRX) United States $0.069B 0.00
Orgenesis (ORGS) United States $0.067B 0.00
Signal Genetics (MGEN) United States $0.065B 0.00
Organovo Holdings (ONVO) United States $0.065B 0.00
ARAVIVE, INC (ARAV) United States $0.064B 0.00
Sunesis Pharmaceuticals (SNSS) United States $0.062B 0.00
Alimera Sciences (ALIM) United States $0.062B 0.00
Protalix BioTherapeutics (PLX) Israel $0.061B 0.00
Invo BioScience (IVOB) United States $0.059B 0.00
Antibe Therapeutics (ATBPF) Canada $0.059B 0.00
Prima BioMed (IMMP) Australia $0.058B 0.00
NewLink Genetics (NLNK) United States $0.054B 0.00
Oncobiologics (OTLK) United States $0.052B 0.00
DiaMedica Therapeutics (DMAC) United States $0.051B 0.00
Vascular Biogenics (VBLT) Israel $0.051B 0.00
Proteostasis Therapeutics (PTI) United States $0.050B 0.00